726136-65-8Relevant articles and documents
Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones
Boyd, Helen F.,Fell, Stephen C.M.,Hickey, Deirdre M.B.,Ife, Robert J.,Leach, Colin A.,Macphee, Colin H.,Milliner, Kevin J.,Pinto, Ivan L.,Rawlings,Smith, Stephen A.,Stansfield, Ian G.,Stanway, Steven J.,Theobald, Colin J.,Whittaker, Caroline M.
, p. 51 - 55 (2002)
A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A2 with high potency in whole human plasma. 5-(Pyrazolylmethyl) derivative 16 and 5-(methoxypyrimidinylmethyl) derivative 27 demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects.
